On March 12, 2025, Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class cancer therapies targeting the Hippo pathway, announced the closing of a $35 million Series D financing. The round was led by RA Capital Management, an existing investor, and included investment from other existing investors Canaan Partners and Cenova Capital. Wilson Sonsini Goodrich & Rosati advised Vivace on patent matters related to the transaction.

Proceeds from the financing will support the continued clinical development of the company's first-in-class and best-in-class transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor, VT3989, with an initial focus on mesothelioma.

The Wilson Sonsini team that advised Vivace on patent matters related to the transaction was led by Uale Taotafa, and included Mike Hostetler and Jim Malecha.

For more information, please see Vivace’s press release.